1-3 of 3
Andrea Marra
Close
Sort by
Journal Articles

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML

Vincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, Stefania Galimberti, Gaia Alberti, Giulia Pianigiani, Valerio Ciaurro, Andrea Marra, Marcella Sabino, Valentina Tini, Giulio Spinozzi, Federica Mezzasoma, Francesco Morena, Sabata Martino, Domenico Salerno, Julian François Ashby, Brittany Wingham, Marta Serafini, Maria Paola Martelli, Brunangelo Falini, Andrea Biondi, Sarah Tettamanti
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2855–2871.
https://doi.org/10.1182/bloodadvances.2022008762
Published: 2023
Includes: Multimedia, Supplemental data
Journal Articles

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1 -mutated AML

Clinical Trials & Observations
Giulia Pianigiani, Andrea Gagliardi, Federica Mezzasoma, Francesca Rocchio, Valentina Tini, Barbara Bigerna, Paolo Sportoletti, Simona Caruso, Andrea Marra, Sara Peruzzi, Eleonora Petito, Giulio Spinozzi, Sharon Shacham, Yosef Landesman, Concetta Quintarelli, Paolo Gresele, Franco Locatelli, Maria Paola Martelli, Brunangelo Falini, Lorenzo Brunetti
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5938–5949.
https://doi.org/10.1182/bloodadvances.2022007563
Published: 2022
Includes: Supplemental data
Journal Articles

Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness

Chiara Pirillo, Flora Birch, Floriane S. Tissot, Sara Gonzalez Anton, Myriam Haltalli, Valentina Tini, Isabella Kong, Cécile Piot, Ben Partridge, Constandina Pospori, Karen Keeshan, Salvatore Santamaria, Edwin Hawkins, Brunangelo Falini, Andrea Marra, Delfim Duarte, Chiu Fan Lee, Edward Roberts, Cristina Lo Celso
Journal: Blood Advances
Blood Adv (2022) 6 (10): 3126–3141.
https://doi.org/10.1182/bloodadvances.2021004321
Published: 2022
Includes: Multimedia, Supplemental data